DiamiR Biosciences Corp. (DIMR)

DiamiR Biosciences Balance Sheet

Financials in millions USD. Fiscal year is June - May.

Year Ending	TTM	May 31, 2023	May 31, 2022
Cash & Equivalents	0.14	0.18	0.29
Cash & Cash Equivalents	0.14	0.18	0.29
Cash Growth	-	-37.30%	-
Receivables	0.08	-	0.01
Other Current Assets	0.06	0.03	0.01
Total Current Assets	0.28	0.21	0.31
Property, Plant & Equipment	-	0.06	0.08
Goodwill and Intangibles	-	0.25	0.26
Total Long-Term Assets	-	0.31	0.34
Total Assets	-	0.52	0.65
Accounts Payable	-	0.04	0.09
Current Debt	-	0.04	0.03
Other Current Liabilities	0.21	0	0
Total Current Liabilities	0.21	0.08	0.12
Long-Term Debt	-	0.42	1.02
Other Long-Term Liabilities	-	0.05	0
Total Long-Term Liabilities	-	0.47	1.02
Total Liabilities	-	0.54	1.14
Total Debt	0.59	0.46	1.05
Debt Growth	-	-56.67%	-
Retained Earnings	-	-4.46	-3.15
Shareholders' Equity	-0.3	-0.02	-0.49
Net Cash / Debt	-0.44	-0.28	-0.76
Working Capital	0.06	0.14	0.19

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).